Google’s Life Sciences division has been confirmed as the first company to be spun-off under the new Alphabet parent company.
The health-focused team, which had been part of Google’s X Labs, has become known for a focus on battling ailments associated with the aging process.
Life Sciences has hit the headlines for a contact lens that can be used to detect signs of diabetes, while the Calico team has been embarking on “moonshot thinking around healthcare and biotechnology” as relates to illness and aging.
Both will now sit under the Life Sciences banner, along with the in-development nanodiagnostics program, which could be used to detect disease earlier, and the Baseline Study, which focuses on mapping the human genome.
In a Google+ post on Thursday, Alphabet president Segey Brin wrote: "I am delighted to announce that the life sciences team is now ready to graduate from our X lab and become a standalone Alphabet company, with Andy Conrad as CEO.
"They’ll continue to work with other life sciences companies to move new technologies from early stage R&D to clinical testing — and, hopefully — transform the way we detect, prevent, and manage disease.
"The team is relatively new but very diverse, including software engineers, oncologists, and optics experts. This is the type of company we hope will thrive as part of Alphabet and I can’t wait to see what they do next."
The spin-off of the company previously known as Google Life Sciences - so not much change there then - evidences Larry Page’s sentiments when explaining the decision to shift to Alphabet.
Page had claimed: “This newer Google is a bit slimmed down, with the companies that are pretty far afield of our main internet products contained in Alphabet instead.”